Skip to main content

Advertisement

Figure 2 | BMC Infectious Diseases

Figure 2

From: Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices

Figure 2

Projected population-level HIV impact in Gauteng for different assumptions about gel efficacy, uptake and use, and its influence on condom use**. **Main shaded bars show best-fit model projections and error bars indicate range spanned by 95% of all model fits (2.5% to 97.5% percentile range or 95% credibility interval), with the dark bars illustrating the main scenario (54% HIV efficacy and 71% HSV-2 efficacy, gel uptake reaching 30% by year 10, gel used in 72% of sex-acts, and no reduction in condom use).

Back to article page